Methods and Compositions for Preventing a Condition

Abstract

Provided herein are methods, compositions, and kits for preventing, inhibiting, reducing the severity of, or treating a disease or condition. A pharmaceutical composition provided herein can comprise a nucleic acid sequence encoding an antigen fused to an immune cell product, e.g., MIP-3α, and an adjuvant. The antigen can be from a bacteria, virus, fungus, parasite, or cancer. The antigen can be an Alzheimer's disease antigen.

1 . A pharmaceutical composition comprising:
 a. a nucleic acid sequence encoding an antigen or a fragment thereof fused to macrophage inflammatory protein 3 alpha or a fragment thereof; and   b. an adjuvant.   
     
     
         2 . The pharmaceutical composition of  claim 1 , wherein the antigen or a fragment thereof is a cancer antigen. 
     
     
         3 . (canceled) 
     
     
         4 . (canceled) 
     
     
         5 . The pharmaceutical composition of  claim 1 , wherein the antigen or a fragment thereof is from a parasite. 
     
     
         6 . (canceled) 
     
     
         7 . (canceled) 
     
     
         8 . (canceled) 
     
     
         9 . The pharmaceutical composition of  claim 1 , wherein the adjuvant is a liposome. 
     
     
         10 . (canceled) 
     
     
         11 . The pharmaceutical composition of  claim 1 , further comprising a regulatory T-cell inhibitor. 
     
     
         12 . The pharmaceutical composition of  claim 11 , wherein the regulatory T-cell inhibitor is an siRNA. 
     
     
         13 . The pharmaceutical composition of  claim 1 , wherein the nucleic acid sequence is a plasmid. 
     
     
         14 . The pharmaceutical composition of  claim 1 , wherein the nucleic acid sequence encodes human macrophage inflammatory protein 3 alpha or a fragment thereof. 
     
     
         15 . A nucleic acid sequence encoding a parasite antigen fused to macrophage inflammatory protein 3 alpha. 
     
     
         16 . The nucleic acid sequence of  claim 15  wherein the parasite is  Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malaria , or  Plasmodium yoelii.    
     
     
         17 . The nucleic acid sequence of  claim 16  wherein the antigen is a circumsporozoite protein or fragment thereof. 
     
     
         18 . The nucleic acid sequence of  claim 17  wherein the circumsporozoite protein or fragment thereof is from  Plasmodium falciparum.    
     
     
         19 . The nucleic acid sequence of  claim 17 , wherein the nucleic acid sequence encodes human macrophage inflammatory protein 3 alpha or a fragment thereof. 
     
     
         20 . (canceled) 
     
     
         21 . (canceled) 
     
     
         22 . (canceled) 
     
     
         23 . (canceled) 
     
     
         24 . (canceled) 
     
     
         25 . (canceled) 
     
     
         26 . (canceled) 
     
     
         27 . (canceled) 
     
     
         28 . (canceled) 
     
     
         29 . (canceled) 
     
     
         30 . (canceled) 
     
     
         31 . (canceled) 
     
     
         32 . (canceled) 
     
     
         33 . (canceled) 
     
     
         34 . (canceled) 
     
     
         35 . (canceled) 
     
     
         36 . (canceled) 
     
     
         37 . (canceled) 
     
     
         38 . (canceled) 
     
     
         39 . (canceled) 
     
     
         40 . A method for eliciting an immune response in a subject comprising administering to the subject a pharmaceutical composition comprising a nucleic acid sequence encoding a parasite antigen or fragment thereof fused to an immune cell product. 
     
     
         41 . The method of  claim 40  wherein the pharmaceutical composition further comprises an adjuvant. 
     
     
         42 . The method of  claim 41  wherein the adjuvant comprises a commixture of GAPDMORIE and DPyPE. 
     
     
         43 . The method of  claim 40  wherein the immune cell product is macrophage inflammatory protein 3 alpha. 
     
     
         44 . The method of  claim 40  wherein the parasite antigen is from  Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malaria , or  Plasmodium yoelii.    
     
     
         45 . (canceled) 
     
     
         46 . (canceled) 
     
     
         47 . (canceled) 
     
     
         48 . The method of  claim 40  wherein the pharmaceutical composition comprises the regulatory T-cell inhibitor. 
     
     
         49 .- 98 . (canceled)